Strong Buy Rating for Roivant Sciences Backed by Strategic …
WEB1 day ago · Chris Shibutani has given his Buy rating due to a combination of factors including the strategic divestiture of Dermavant and the promising clinical pipeline of Roivant Sciences.
Roivant Sciences Offloads Psoriasis Medicine Maker To Organon …
WEB2 days ago · Organon & Co (NYSE:OGN) has agreed to acquire Roivant Sciences Ltd’s (NASDAQ:ROIV) Dermavant Sciences Ltd, which is focused on developing and commercializing therapeutics in immunodermatology.
Organon makes $1.2bn play for Roivant’s immuno-dermatology …
WEB22 hours ago · Organon is set to acquire Roivant’s immuno-dermatology subsidiary Dermavant in a potential $1.2bn deal. Organon will pay $175m upfront for the business as part of the transaction, which is ...
Roivant dermatology subsidiary to be acquired by Organon
WEB2 days ago · Organon has agreed to buy Roivant’s dermatology subsidiary Dermavant for $175 million upfront plus more than $1 billion in potential additional payments if certain milestones are hit. With the acquisition, Organon will gain Dermavant’s cream called Vtama, which was approved in 2022 to treat plaque psoriasis. The medicine is also awaiting ...
News & Press Releases | Roivant
WEBJul 19, 2024 · Financially, Roivant is well-capitalized with $6.67 billion in cash against minimal liabilities. Investment recommendation: Buy Roivant as part of a high-risk segment of a diversified portfolio. Roivant spinoff tackles growing complexity of clinical trials.
Roivant sells dermatology spinoff to Organon in deal worth $1.2 …
WEB1 day ago · Roivant Sciences continues its dealmaking hot streak, announcing Wednesday that it would sell one of its subsidiaries to pharma company Organon in a deal worth $1.2 billion.
Organon to Acquire Dermavant including its Innovative …
WEB2 days ago · Dermavant has been developing VTAMA cream for the treatment of atopic dermatitis in adults and children 2 years of age and older and released positive topline results from its ADORING 1 and 2 pivotal Phase 3 clinical trials in 1H 2023.
Roivant Unveils New Pipeline Program Mosliciguat, A Potential …
WEBSep 10, 2024 · Today, Roivant’s pipeline includes VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting the neonatal Fc receptor (“FcRn”) in development across several IgG-mediated autoimmune indications; and ...
Roche Completes Acquisition of Telavant from Roivant, Including …
WEBDec 14, 2023 · BASEL, Switzerland and LONDON and NEW YORK, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) announced today the completion of the previously announced acquisition by Roche (SIX: RO, ROG; OTCQX: RHHBY) of Telavant, for an upfront payment of approximately $7.1 billion.
Roivant Sciences Unveils New 'Vant' Subsidiary For In-Licensed ...
WEBSep 10, 2024 · Roivant Sciences Unveils New 'Vant' Subsidiary For In-Licensed Pulmonary Hypertension Drug From Bayer. Tuesday, Roivant Sciences Ltd. (NASDAQ: ROIV) created Pulmovant to in-license from Bayer...
Skip to content